NASDAQ: MBX

MBX Biosciences, Inc. Common Stock

Healthcare | Biotechnology

$66.78 as of 2026-09-04 22:26 UTC

Market Cap$3.2B

Volume217.7K

MBX Biosciences, Inc. Common Stock (NASDAQ: MBX) is a $3.2B biotechnology company trading at $66.78. Figures from SEC EDGAR and market feeds; updated 2026-09-04 22:26 UTC.

What MBX Biosciences, Inc. Common Stock does

The company is a clinical-stage biopharmaceutical organization developing precision peptide therapies for endocrine and metabolic disorders using its proprietary PEP platform, which is designed to create peptides with extended duration, low peak-to-trough ratios, and less frequent dosing requirements. The lead product, canvuparatide, is a PTH peptide prodrug for chronic hypoparathyroidism that completed a Phase 2 trial and is expected to advance to Phase 3 in the third quarter of 2026.

Summarized from MBX Biosciences, Inc. Common Stock’s SEC filings · Read the filing ↗

Key facts

Quote	22:26 UTC
Price	$66.78
Market cap	$3.2B
Volume	217.7K shares

Price Chart

Interactive chart available in terminalLive price charts with full OHLCV data, volume overlay, and technical indicators.
Open MBX in Platform →

SEC Filings

SEC EDGAR ↗

Recent Insider Activity (last 90 days)

Source: SEC EDGAR · Filed 2026-08-05

2026-08-05Azoulay SalomonChief Medical OfficerSELL-370$24.3K
2026-08-04Smither John WChief Financial OfficerA130,000—
2026-08-04Smither John WChief Financial OfficerA28,000—

Top Institutional Holders (latest 13F)

Source: SEC EDGAR · As of 2026-Q1

FMR LLC5,322,885$293.82M+87.1%
WELLINGTON MANAGEMENT GROUP LLP4,977,523$274.76M+61.0%
Frazier Life Sciences Management, L.P.6,652,013$198.56M0.0%

View QoQ ownership changes →Full institutional ownership →

Recent 8-K Events (parsed from SEC filings)All events →

Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

2026-07-13Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2026-02-27Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →

Company news

View all →

MBX Biosciences, Inc. (MBX) Discusses One-Year Data From Phase II Open-Label Extension Study of Once-Weekly Canvuparatide Transcript
seekingalpha.com2026-06-12
MBX Biosciences, Inc. (MBX) Discusses One-Year Data From Phase II Open-Label Extension Study of Once-Weekly Canvuparatide Transcript
Seeking Alpha Feed2026-06-12
MBX Biosciences, Inc. (MBX) Discusses Novel Approaches and Clinical Progress in Obesity Therapeutics Portfolio Transcript
seekingalpha.com2026-05-11
MBX Biosciences Obesity Day Spotlights Monthly GLP-1 Hope and Pipeline Push
marketbeat.com2026-05-11

Questions this page answers

What does MBX Biosciences, Inc. Common Stock do?

MBX Biosciences, Inc. Common Stock is a biotechnology company, listed on NASDAQ as MBX.

What is MBX's valuation?

MBX trades at $66.78, as of 2026-09-04.

When did MBX last file with the SEC?

MBX Biosciences, Inc. Common Stock's most recent SEC filing on record is a 10-Q filed 2026-08-06. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings and public market data feeds, fetched 2026-09-04 22:26 UTC. This page is also available as JSON at /api/data?ticker=MBX and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for MBX and 5,000+ tickers.

Create a free account — keep MBX

For your agent

GET /api/data?ticker=MBX

This page as JSON via rel="alternate" · REST API docs · MCP server (59 tools) · llms.txt